MAZE
Maze Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +5.6% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 64 | +2 | 15.19M | $452.36M | +8 | −6 |
| Q1 2026 | 65 | +7 | 14.90M | $445.37M | +11 | −4 |
| Q4 2025 | 57 | +5 | 12.83M | $531.64M | +5 | — |
| Q3 2025 | 12 | +3 | 5.31M | $137.60M | +3 | — |
| Q2 2025 | 7 | 0 | 2.01M | $24.69M | +1 | −1 |
| Q1 2025 | 4 | +4 | 316.77K | $3.49M | +4 | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 614.70K | — | $7.54M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 614.70K | — | $7.54M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 614.70K | — | $7.54M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | BlackRock ✦ (passive) | 614.70K | — | $7.54M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | BlackRock ✦ (passive) | 614.70K | — | $7.54M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Fidelity (FMR) ✦ | 554.53K | — | $6.80M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Fidelity (FMR) ✦ | 554.53K | — | $6.80M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | The Vanguard Group ✦ (passive) | 419.61K | — | $5.15M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | The Vanguard Group ✦ (passive) | 419.61K | — | $5.15M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | The Vanguard Group ✦ (passive) | 419.61K | — | $5.15M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 231.24K | +8.8% | $2.84M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passive) | 231.24K | +8.8% | $2.84M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | State Street Global Advisors ✦ (passive) | 144.69K | +123.6% | $1.78M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 27.47K | New | $337,020 | 0.0% | New | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 27.47K | New | $337,020 | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 27.47K | New | $337,020 | 0.0% | New | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 27.47K | New | $337,020 | 0.0% | New | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 27.47K | New | $337,020 | 0.0% | New | 1 | SEC ↗ |
| 19 | Marshall Wace ✦ | 19.60K | 0.0% | $240,455 | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $337,020 | 0.0% |
| AQR Capital Management | $337,020 | 0.0% |
| AQR Capital Management | $337,020 | 0.0% |
| AQR Capital Management | $337,020 | 0.0% |
| AQR Capital Management | $337,020 | 0.0% |
Exited
| Citadel Advisors | $220,200 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 164 holders, 51.62M shares, $1.52B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 16.14K sh · $445,621
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology